Biomarker innovations in precision psychiatry diagnostics and treatment strategies

Martien J H Kas; Kim Q Do; Michael S Sand; Rouba Kozak; Elizabeth M Tunbridge; Maria A Oquendo; Carol Tamminga; Nikolaos Koutsouleris; Gitte Moos Knudsen; Brenda W J H Penninx; Frank J Padberg; Wayne C Drevets; Peter Falkai; Derek L Buhl; Andreas Reif

doi:10.1016/j.euroneuro.2026.112762

Biomarker innovations in precision psychiatry diagnostics and treatment strategies

Eur Neuropsychopharmacol. 2026 Jan 15:105:112762. doi: 10.1016/j.euroneuro.2026.112762. Online ahead of print.

Authors

Affiliations

¹ Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, the Netherlands. Electronic address: m.j.h.kas@rug.nl.
² Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
³ S2 Consulting LLC, Danbury, CT, USA.
⁴ Foundation for the National Institute of Health, Cambridge, MA, USA.
⁵ Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
⁶ Perelman School of Medicine, University of Pennsylvania, PA, USA.
⁷ Department of Psychiatry, UT Southwestern Medical School, Dallas, TX, USA.
⁸ Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, United Kingdom; Department of Psychiatry, Ludwig-Maximilians-University München, Germany; Max-Planck-Institute for Psychiatry, Munich, Germany; Munich-Augsburg Site of the German Centre for Mental Health (DZPG), Germany.
⁹ Neurobiology Research Unit, Copenhagen University Hospital (Rigshospitalet) and Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
¹⁰ Department of Psychiatry, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands.
¹¹ Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Germany.
¹² Department of Neuroscience, Janssen Research & Development, LLC, of Johnson & Johnson, San Diego, CA, USA.
¹³ Department of Psychiatry, Ludwig-Maximilians-University München, Germany; Max-Planck-Institute for Psychiatry, German Center of Mental Health (DZPG), Munich, Germany.
¹⁴ Neuroscience Precision Medicine, AbbVie, Inc., Cambridge, MA 02139, USA.
¹⁵ Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Medical Center Frankfurt, Frankfurt am Main, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, Frankfurt am Main 60596, Germany.

PMID: 41544575
DOI: 10.1016/j.euroneuro.2026.112762

Abstract

Precision psychiatry is an approach designed to improve diagnosis and treatment of mental disorders by leveraging biological insights and developing innovative, mechanism-based treatment strategies unconstrained by current diagnostic boundaries. At its core, precision psychiatry aims to pinpoint the underlying neurobiological mechanisms responsible for the emergence and persistence of symptoms of mental health conditions. This approach strives to create diagnostic tools and therapies targeting these mechanisms, potentially addressing previously resistant aspects of mental health conditions by providing more precise symptom management and possibly altering the disease trajectory. Although still in its nascent stages, the realization of precision psychiatry will result in a more refined and biology-informed diagnostic system for mental disorders, requiring significant adaptations for clinicians, industry, patients and regulators. Identifying, validating and applying both fluid and functional biomarkers are critical steps in the development, testing and application of new precision psychiatry diagnostics and treatments. As part of the 2025 Precision Psychiatry Roadmap initiative meeting in Frankfurt, experts came together to present and discuss the current status of biomarker identification and validation, patient subtyping, and targeted interventions for stratified patient groups. This report features lecture summaries, meeting outcomes, and recommendations from both online and in-person audiences. In general, the recommendations emphasize standardization, collaboration, clinical implementation, digital innovation, long-term planning, and, importantly, patient engagement, as key priorities for advancing precision psychiatry. Despite existing challenges, there is strong optimism for the future of precision psychiatry, with continuous efforts to refine diagnostic tools and treatment strategies.

Keywords: Behavior; Diagnose; Diagnostic strategy; EEG; Neuro-imaging; Neuroscience; Stratification.